AU2022308094A1 - Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same - Google Patents

Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same Download PDF

Info

Publication number
AU2022308094A1
AU2022308094A1 AU2022308094A AU2022308094A AU2022308094A1 AU 2022308094 A1 AU2022308094 A1 AU 2022308094A1 AU 2022308094 A AU2022308094 A AU 2022308094A AU 2022308094 A AU2022308094 A AU 2022308094A AU 2022308094 A1 AU2022308094 A1 AU 2022308094A1
Authority
AU
Australia
Prior art keywords
seq
peptide
polypeptides
polypeptide
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022308094A
Other languages
English (en)
Inventor
Vladimir Armando BESADA PÉREZ
Evelin CABALLERO MENÉNDEZ
Hilda Elisa GARAY PÉREZ
Sonia Gonzalez Blanco
Luis Javier GONZÁLEZ LÓPEZ
Gerardo Enrique GUILLÉN NIETO
Yordanka MASFORROL GONZÁLEZ
Silvio Ernesto PEREA RODRÍGUEZ
Yasser Perera Negrin
Osvaldo Reyes Acosta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of AU2022308094A1 publication Critical patent/AU2022308094A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2022308094A 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same Pending AU2022308094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2
CU2021-0058 2021-07-09
PCT/CU2022/050007 WO2023280330A1 (es) 2021-07-09 2022-07-07 Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Publications (1)

Publication Number Publication Date
AU2022308094A1 true AU2022308094A1 (en) 2024-02-01

Family

ID=83080989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022308094A Pending AU2022308094A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same

Country Status (11)

Country Link
US (1) US20240317827A1 (https=)
EP (1) EP4368710A1 (https=)
JP (1) JP2024534231A (https=)
KR (1) KR20240032882A (https=)
CN (1) CN117795064A (https=)
AR (1) AR126388A1 (https=)
AU (1) AU2022308094A1 (https=)
CA (1) CA3225387A1 (https=)
CU (1) CU24766B1 (https=)
MX (1) MX2024000542A (https=)
WO (1) WO2023280330A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118290537B (zh) * 2024-05-09 2025-02-07 永州中古生物技术有限公司 一种在nci-h460细胞系中对ck2起到抑制作用的多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
WO2006020207A2 (en) * 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides

Also Published As

Publication number Publication date
CU24766B1 (es) 2025-08-13
WO2023280330A1 (es) 2023-01-12
JP2024534231A (ja) 2024-09-18
CU20210058A7 (es) 2023-02-13
US20240317827A1 (en) 2024-09-26
KR20240032882A (ko) 2024-03-12
MX2024000542A (es) 2024-02-02
EP4368710A1 (en) 2024-05-15
AR126388A1 (es) 2023-10-11
CN117795064A (zh) 2024-03-29
CA3225387A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
US8765909B2 (en) Metastin derivatives and use thereof
CA2473032A1 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
JPH03101695A (ja) Ｌｈｒｈ同族体
ES2375038T3 (es) Derivados de metastina y su uso.
CN111040020A (zh) 一种烯烃硫醚类订书肽及其制备方法与应用
CN111690041B (zh) 一类具有抗肿瘤活性多肽及其制备方法
JP2017523957A (ja) Ｄ−アルギニル−２，６−ジメチル−ｌ−チロシル−ｌ−リシル−ｌ−フェニルアラニンアミドの製造方法
WO2015022283A1 (en) Yap-tead inhibitors
US20240317827A1 (en) Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
AU2005254736B2 (en) Oligomeric peptides and their use for the treatment of HIV infections
JP2001103993A (ja) 環状ペプチド及びセリンプロテアーゼ阻害剤
US20090093615A1 (en) Metastin derivatives and use thereof
CN102816213A (zh) 使用固相和液相组合技术制备普兰林肽的方法
AU641197B2 (en) Inhibitors of retroviral proteases
EP1345957A2 (en) Inhibitors of the e2f-1/cyclin interaction for cancer therapy
CN115160406A (zh) 一类新型抗肿瘤环肽活性分子的制备方法与应用
EP0673388B1 (en) Double chain peptide compounds having hemoregulatory activity
KR20040090965A (ko) Ｌｈｒｈ 길항제 합성용 중간체, 그 제조 방법 및ｌｈｒｈ 길항제의 제조 방법
CA1284550C (en) Retro-inverso analogs of the bradykinin potentiating peptide bpp*in5a*xx
CA2118253A1 (en) Tachiquinine antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
AU2023374544A1 (en) Ccr2 inhibitors and methods of use
Kotoku et al. Absolute stereo-structure of kendarimide A, a novel MDR modulator, from a marine sponge
EP4063380A1 (en) Inhibitors of the wnt signaling pathway and uses thereof
WO2025186255A1 (en) Gipr inhibitors and methods of use
WO2025043696A1 (zh) 抗病毒多肽类似物